A deletion mutant of Pseudomonas exotoxin-A fused to recombinant human interleukin-9 (rhlL-9-ETA') shows specific cytotoxicity against IL-9-receptor-expressing cell lines

Cytokines and Molecular Therapy

Volumn 2, Issue 3, 1996, Pages 139-146

  Klimka, A ^a,b   Barth, S ^a,b   Drillich, S ^a,c   Wes, W ^a   Van Snick, J ^a   Renauld, J C ^a,c   Tesch, H ^a,c   Bohlen, H ^a,c   Diehl, V ^a,c   Engert, A ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b TUMOR BIOLOGY CENTER   (Germany)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Belgium)

Author keywords

Acute myelold leukemia; Hodgkin's lymphoma; Immunotherapy; Interleukin 9; Recombinant immunotoxin

Indexed keywords

ANTIBODY; COMPLEMENTARY DNA; HYBRID PROTEIN; INTERLEUKIN 9; INTERLEUKIN RECEPTOR; MUTANT PROTEIN; PROTEIN; PSEUDOMONAS EXOTOXIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BURKITT LYMPHOMA; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CELL STRAIN K 562; CONTROLLED STUDY; CYTOTOXICITY; DAUDI CELL; DELETION MUTANT; DNA TRANSFECTION; ERYTHROLEUKEMIA CELL; HUMAN; HUMAN CELL; MASTOCYTOMA; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; PSEUDOMONAS; PSEUDOMONAS AERUGINOSA; RECEPTOR BINDING; REED STERNBERG CELL;

ADP RIBOSE TRANSFERASES; ANIMALS; BACTERIAL TOXINS; BURKITT LYMPHOMA; CELL SURVIVAL; CLONING, ORGANISM; ESCHERICHIA COLI; EXOTOXINS; HUMANS; IMMUNOTHERAPY; IMMUNOTOXINS; INTERLEUKIN-9; MAST-CELL SARCOMA; MUTAGENESIS, SITE-DIRECTED; POLYMERASE CHAIN REACTION; PSEUDOMONAS AERUGINOSA; RECEPTORS, INTERLEUKIN; RECEPTORS, INTERLEUKIN-9; RECOMBINANT FUSION PROTEINS; RECOMBINANT PROTEINS; SEQUENCE DELETION; TRANSFECTION; TUMOR CELLS, CULTURED; VIRULENCE FACTORS;

EID: 0029845846     PISSN: 13556568     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Vitetta E, Thorpe PE, Uhr JW, Immunotoxins: magic bullets or misguided missiles? Imnnmol Today (1993) 14:252-9.
2. Vitetta ES, Stone M, Amlot P et al, Phase I IT trial in patients with B-cell lymphoma. Cancer Res (1991) 51: 4052-58.
3. Amlot P, Stone MJ, Cunningham D et al, A phase-I study of an anti-CD22-deglycosylated ricin A-chain IT in the treatment of B-cell lymphomas resistant to conventional therapy. Blood (1993) 82: 2624-33.
4. Grossbard ML, Lambert JM, Goldmacher VS et al, Anti-B4-blocked ricin. A phase I trial of 7-day continuous infusion in patients with B-cell neoplasms. J Clin OHO?/(1993) 11: 726-37.
5. Engert A, Burrows F, Jung W et al, Evaluation of ricin A-chain containing immunotoxins directed against CD30 as potential reagents for the treatment of Hodgkin's disease. Cancer Res (1990) 50: 84-8.
6. Engert A, Gottstein C, Winkler U et al, Experimental treatment of Hodgkin's disease with ricin A-chain immunotoxins. Leuk Lymphoma (1994) 13: 441-8.
7. Engert A, Schnell R, Schindler J et al, A phase I trial with the chemically-linked ricin-A chain immunotoxin, RFT5-SMPT-dgA (CD25), in patients with refractory Hodgkin's disease. Blood (1996), in press.
8. Falini B, Bolognesi A, Flenghi L et al, Response of refractory Hodgkin's disease to monoclonal antiCD30 IT. Lancet (1992) 339: 1195-6.
9. Juecker M, Abts H, Li W et al, Expression of interleukin-6 and interleukin-6 receptor in Hodgkin's disease. Blood (1991) 77: 2413-18.
10. Gruss HJ, Brach MA, Drexler HG et al, Interleukin 9 is expressed by primary and cultured Hodgkin and Reed-Sternberg cells. Cancer Res (1992) 52: 1026-31.
11. Yang YC, Ricciardi S, Ciarletta A et al, Expression cloning of a cDNA encoding a novel human haematopoetic growth factor: human homologue of murine T-cell growth factor P40. Blood (1989) 74: 1880-4.
12. Renauld JC, Goethals A, Houssiau F et al, Cloning and expression of a cDNA for the human homologue of mouse T cell and mast cell growth factor P40. Cytokine (1990) 2: 9-12.
13. Modi WS, Pollock DD, Mock B A et al, Regional localization of the human glutaminase (GLS) and interleukin-9 (IL9) genes by in situ hybridization. Cytogenet Cell Genet (1991) 57: 114-16.
14. Merz H, Houssiau FA, Orscheschek K et al, Interleukin-9 expression in human malignant lymphomas: unique association with Hodgkin's disease and large cell anaplastic lymphoma. Blood (1991) 78: 1311-17.
15. Kelleher K, Bean K, Clark SC et al, Human interleukin-9: genomic sequence, chromosomal location, and sequences essential for its expression in human T-cell leukemia virus (HTLV)-I-transformed human T-cells. Blood (1991) 77: 1436-41.
16. Renauld JC, Kermouni A, Vink A et al, Interleukin-9 and its receptor: involvement in mast cell differentiation and T cell oncogenesis. J Leukocyte Biol (1995) 57: 353-60.
17. Thorpe PE, Wallace PM, Knowles PP et al, Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages. Cancer Res (1988) 48: 6396-403.
18. GhetieMA, Tucker K, Richardson Jet al, The antitumor activity of an anti-CD22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD 19 antibody or an anti-CD 19 immunotoxin. Blood (1992) 80: 2315-20.
19. Engert A, Gottstein C, Bohlen H et al, Cocktails of ricin A-chain immunotoxins against different antigens on Hodgkin and Sternberg-Reed cells have superior antitumor effects against H-RS cells in vitro and solid Hodgkin tumors in mice. Jntjf Cancer (1995) 63: 304-9.
20. Wels W, Harwerth IM, Mueller M et al, Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor. Cancer Res (1992) 52: 6310-17.
21. Diehl V, von Kalle C, Fonatsch C, The cell of origin in Hodgkin's disease. Sem Oncol (1990) 17: 660-72.
22. Kamesaki H, Fukuhara S, Tatsumi E et al, Cytochemical, immunologie, chromosomal and molecular genetic analysis of a novel cell line derived from Hodgkin's disease. Blood (1986) 68: 285-92.
23. Wolf J, Kapp U, Bohlen H et al, Peripheral blood mononuclear cell of patient with advanced Hodgkin's lymphoma give rise to permanently growing Hodgkin-Reed-Sternberg cells. Blood (1996) 87: 3418-28.
24. Klein E, Klein G, Nadkarni NJ et al, Surface IgMkappa specificity on a Burkitt lymphoma cell in vivo and in derived culture lines. Cancer Res (1968) 18: 1300-10.
25. Lozzio CB, Lozzio BB, Human chronic myelogenous cell line with positive Philadelphia chromosome. Blood (1975) 45:321-34.
26. Wels W, Harwerth IM, Zwickl M et al, Construction, bacterial expression and characterization of a bifunctional single-chain antibody-phosphate fusion protein targeted to the human erbB-2 receptor. BiolTechnol (1992) 10:1128-32.
27. Wels W, Beerli R, Hellmann P et al, EGF receptor and p!85"bB'2-specific single-chain antibody toxins differ in their cell-killing activity on tumor cells expressing both receptor proteins. Int J Cancer (1995) 60: 137-44.
28. Gray GL, Smith DH, Baldridge JS et al, Cloning, nucleotide sequence and expression in Escherichia coli of the exotoxin A structural gene of Pseitdomonas aemginosa. Proc Natl Acad Sei USA (1984) 81: 2645-9.
29. Prickelt KS, Amberg DC, Hopp TP, A calciumdependent antibody for identification and purification of recombinant proteins. Biotech (1989) 7: 580-9.
30. Hochuli E, Dobeli H, Schacher A, New metal chelate adsorbent selective for proteins and peptides containing neighbouring histidine residues. J Chromatogr (1987) 411: 177-84.
31. Manoil C, Beckwith J, Tupho A: a transposon probe for protein export signals. Proc Natl Acad Sei USA (1985) 82: 8129-33.
32. Pfreundschuh M, Mommertz E, Meissner M et al, Hodgkin and Reed-Sternberg cell associated monoclonal antibodies HRS-1 and HRS-2 react with activated cells of lymphoid and monocytoid origin. Anticancer Res (1988) 8: 217-24.
33. Galloway DR, Hedstrom RC, Pavlovskis OR, Production and characterization of monoclonal antibodies to exotoxin A from Pseudomonas aeruginosa. Infect Immun (1984) 44: 262-7.
34. Chang M, Engel G, Benedict C et al, Isolation and characterization of the human interleukin-9 receptor gene. Blood (1994) 8: 3199-205.
35. Kreitman RJ, Pastan I, Recombinant toxins. Adv Phannacol (1994) 28: 193-219.
36. Brinkmann U, Pai LH, FitzGerald DJ et al, B3(Fv)PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice. Proc Natl Acad Sei USA (1991) 88: 8616-20.
37. Kreitman RJ, Bailon P, Chaudhary VK et al, Recombinant immunotoxins containing anti-TAC (Fv) and derivatives of Pseudomonas exotoxin produce complete regression in mice of an interleukin-2 receptor-expressing human carcinoma. Blood (1994) 2: 426-34.
38. LeMaistre CF, Meneghetti C, Rosenblum M et al, Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hématologie malignancies expressing the IL-2 receptor. Blood (1992) 79: 2547-54.
39. Debinski W, Puri RK, Kreitman RJ, Pastan I, A wide range of human cancers express interleukin 4 (IL4) receptors that can be targeted with chimeric toxin composed of IL4 and Pseudomonas exotoxin. J Biol Cliem (1993) 268: 14 065-70.
40. Siegall CB, Chaudhary VK, FitzGerald DJ, Pastan I, Cytotoxic activity of an interleukin 6-Pseudomonas exotoxin fusion protein on human myeloma cells. Proc Natl Acad Sei USA (1988) 85: 9738-42.
41. Platanias LC, Ratain MJ, O'Brien S et al, Phase I trial of a genetically engineered interleukin-2 fusion toxin (DAB486IL-2) as a 6 hour intravenous infusion in patients with hématologie malignancies. Lenk Lymphoma (1994) 14: 257-62.
42. Foss FM, Borkowski TA, Gilliom M et al, Chimeric fusion protein toxin DAB486IL-2 in advanced mycosis fungoides and the Sezary syndrome: correlation of activity and interleukin-2 receptor expression in a phase II study. Blood (1994) 84: 1765-74.
43. Foss F, Nichols J, Parker K, Phase I/II trial of DAB3S9IL-2 patients with NHL, HD and CTCL. In: Proceedings of 4th International Symposium on Immunotoxins, Myrtle Beach, SC, 1995, p!59A.
44. Kawasaki ES, Clark SS, Coyne MY et al, Diagnosis os chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro. Proc NatlAcad Sei USA (1988) 85: 5698-702.
45. Kermouni A, Van Roost E, Arden KG et al, The IL-9 receptor gene: genomic structure, chromosomal localization in the pseudoautosomal region of the long arm of the sex chromosomes and identification of IL-9R pseudogenes at 9qter, 1 Opter, 1 opter and ISpter. Genomics (1996), in press.
46. Taniguchi T, Minami Y, The IL2/IL-2 receptor system: a current overview. Cell (1993) 73: 5-8.
47. Cosman D, The hematopoietin receptor superfamily. Cytokine (1993) 5: 95-106.
48. Russell SM, Johnston JA, Noguchi M et al, Interaction of IL-2Rb and gc chains with Jakl and Jak3: implications for XSCID and XCID. Science (1994) 266: 1042-5.
49. Kimura Y, Takeshita T, Kondo M et al, Sharing of the IL-2 receptor gamma chain with the functional IL9 receptor complex. Int Itntmmol (1995) 7: 115-20.
50. Siegall CB, Nordan RP, FitzGerald DJ, Pastan I, Cell-specific toxicity of a chimeric protein composed of interleukin-6 and Pseudomonas exotoxin (IL6PE40) on tumor cells. Mol Cell Biol (1990) 10: 2443-7.
51. Shen GL, Li JL, Ghetie MA et al, Evaluation of four CD22 antibodies as ricin A-chain-containing immunotoxins for the in vivo therapy of human B-cell leukemias and lymphomas. Int J Cancer (1988) 42: 792-7.
52. Press OW, Martin PJ, Thorpe PE, Vitetta ES, Ricin A-chain containing immunotoxins directed against different epitopes on the CD2 molecule differ in their ability to kill normal and malignant T cells. J Immunol (1988) 141:4410-17.
53. Vitetta ES, Thorpe PE, Immunotoxins containing ricin or its A-chain. Sem Cell Biol (1991) 2: 47-58.
54. Engert A, Brown A, Thorpe P, Resistance of myeloid leukemia cell lines to ricin A-chain immunotoxins. Leukemia Res (1991) 15: 1079-86.
55. Lemoli RM, Fogli M, Fortuna A et al, Expression and stimulatory activity of interleukin-9 (IL-9) in human myeloid leukemia cells. Blood (1994) 84(suppl 1): 53a.